HCA Healthcare Announces Gene Editing Therapy Research Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
HCA Healthcare announced new research published in The New England Journal of Medicine, NEJM, demonstrating promising results from a gene-editing therapy being investigated in children ages 5-11 with severe sickle cell disease and transfusion-dependent beta thalassemia. The study evaluated exa-cel, a CRISPR-based cell therapy, which is currently approved by the U.S. Food and Drug Administration for eligible patients ages 12 and older with sickle cell disease and transfusion-dependent beta thalassemia. The therapy is designed to work by editing a patient's own blood-forming stem cells to increase production of fetal hemoglobin, which can help prevent or reduce disease complications. The findings were based on two phase 3 studies that enrolled 26 children ages 5-11, including 15 with transfusion-dependent beta thalassemia and 11 with sickle cell disease. Among participants who had been followed long enough to evaluate the study's primary endpoints, all eight children with beta thalassemia achieved transfusion independence for at least 12 months, while all eight children with sickle cell disease remained free from severe vaso-occlusive crises for at least 12 months.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HCA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HCA
Wall Street analysts forecast HCA stock price to rise
19 Analyst Rating
13 Buy
5 Hold
1 Sell
Moderate Buy
Current: 393.240
Low
420.00
Averages
491.89
High
525.00
Current: 393.240
Low
420.00
Averages
491.89
High
525.00
About HCA
HCA Healthcare, Inc. is a health care services company. The Company provides acute care hospitals, ambulatory surgery centers (ASCs), freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, radiation and oncology therapy centers, comprehensive rehabilitation and physical therapy centers, hospices, and various other facilities. Its general, acute care hospitals provide a full range of services to accommodate such medical specialties as internal medicine, general surgery, cardiology, oncology, neurosurgery, orthopedics and obstetrics, as well as diagnostic and emergency services. Its behavioral hospitals provide a full range of mental health care services through inpatient, partial hospitalization and outpatient settings. It operates approximately 190 hospitals comprised of 179 general acute care hospitals, seven behavioral hospitals, and four rehabilitation hospitals and its facilities are in 19 states and the United Kingdom.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Healthcare Stocks Surge Following CMS Payment Rate Proposal
- Healthcare Stocks Surge: Following the CMS proposal to increase payment rates by 2.4% for hospitals and ambulatory surgical centers, shares of Universal Health Services rose 7% and HCA Healthcare increased by 5%, reflecting market optimism towards the healthcare sector.
- Rivian's Delivery Outlook Raised: Rivian Automotive raised its 2026 delivery outlook from 62,000-67,000 to 65,000-70,000, resulting in an 8% stock price increase, indicating strong market confidence in its future growth potential.
- Blue Owl Capital Redemption Pressure Eases: Blue Owl Capital's stock jumped over 4% as a shareholder letter revealed that redemption requests for its private credit funds decreased to $4.7 billion in Q2 from $5.4 billion in Q1, suggesting improved market confidence in its liquidity.
- National Beverage's Special Cash Dividend: National Beverage Corp. announced a special cash dividend of $3.25 per share, leading to a 13% stock price increase, which not only enhances investor returns but may also attract more attention from potential investors.
See More
HCA Healthcare Launches Gene Editing Therapy Research for Children
- Significant Research Findings: HCA Healthcare's study published in The New England Journal of Medicine demonstrates promising results for gene editing therapy in children aged 5-11 with severe sickle cell disease and transfusion-dependent beta thalassemia, with all eight beta thalassemia patients achieving transfusion independence for at least 12 months, highlighting the potential for earlier intervention.
- Clinical Trial Context: The study is based on two phase 3 trials enrolling 26 children, including 15 with beta thalassemia and 11 with sickle cell disease, emphasizing the importance of gene editing therapy in alleviating the disease burden in children.
- Innovative Treatment Mechanism: The therapy works by editing patients' own blood-forming stem cells to increase fetal hemoglobin production, which can help prevent or reduce disease complications, showcasing the application prospects of gene editing technology in blood disorder treatments.
- Expanding Treatment Opportunities: HCA Healthcare is expanding access to FDA-approved gene editing therapies through its Sarah Cannon Transplant and Cellular Therapy Network, with TriStar Centennial Children's Hospital in Nashville and Methodist Children's Hospital in San Antonio currently offering treatments, and Medical City Children's Hospital in Dallas preparing to expand services.
See More
HCA Healthcare Rated as Top Non-Tech Stock by Analysts
- Price Target Cut: TD Cowen has lowered HCA Healthcare's price target from $500 to $431 while maintaining a Buy rating, reflecting a cautious outlook on the company's future growth, particularly after reducing growth assumptions for 2026 and 2027.
- Stagnant Revenue Growth: The May hospital survey indicated flat year-over-year revenue for HCA Healthcare, with weaker surgical volumes partially offset by growth in medical volumes, which could impact the company's overall financial performance.
- Acquisition of Educational Institution: On May 27, HCA Healthcare announced the acquisition of The College of Health Care Professions (CHCP), which educates over 8,000 students annually, highlighting the company's commitment to academic quality and student success while enhancing its talent pipeline in the healthcare sector.
- Long-term Partnership: HCA Healthcare has partnered with CHCP for decades, primarily through clinical sites, program advisory boards, and career placement, and this deep-rooted collaboration is expected to further strengthen the company's influence in healthcare education.
See More
Opportunities in Investing in Quality Stocks on the Dip
- HCA Healthcare Outlook: Despite HCA Healthcare's stock price decline due to economic challenges, its extensive facility network and industry leadership position make it an attractive long-term investment, especially as the aging population drives demand for services.
- MercadoLibre's Strategic Investments: Facing competitive pressures in the Latin American e-commerce market, MercadoLibre's short-term profit decline is offset by investments in financial services and advertising, which are expected to lay the groundwork for future growth and showcase its market potential.
- Visa's Legal Challenges: While Visa is under pressure from antitrust lawsuits and legislative proposals, its strong financial performance and network effects maintain its competitiveness in the digital payments space, indicating continued long-term return potential.
- Market Performance Comparison: Although HCA Healthcare, MercadoLibre, and Visa have recently underperformed, their robust fundamentals suggest that investors should consider increasing their positions during this downturn to potentially reap substantial rewards in the future.
See More
Investment Opportunities in HCA, MercadoLibre, and Visa Amidst Market Challenges
- HCA Healthcare's Market Position: HCA Healthcare boasts a vast network of facilities across the U.S., and despite facing economic challenges, it continues to grow its market share, showcasing its competitive advantage in a high-barrier industry that attracts long-term investors.
- MercadoLibre's Strategic Investments: Facing intense e-commerce competition, MercadoLibre is heavily investing in financial services to establish a leading position in the long run, even though short-term profits and margins are affected, its future potential remains promising.
- Visa's Legal Challenges: Visa is under pressure from antitrust lawsuits and proposed legislation, yet its strong financial performance and network effects position it well for long-term growth in the digital payment space, making it a worthwhile consideration for investors.
- Opportunities for Market Rebound: Despite declines in stock prices due to company-specific issues, HCA, MercadoLibre, and Visa's leadership positions and future growth potential make them attractive investments as the market recovers.
See More
Healthcare, E-commerce, and Payment Giants Face Challenges
- HCA Healthcare's Market Position: HCA Healthcare boasts a vast network of facilities across the U.S., and despite facing economic challenges and high inflation, it continues to grow its market share, demonstrating strong competitiveness in the healthcare sector, making it a buy on dips for long-term investors.
- MercadoLibre's Investment Strategy: Although MercadoLibre faces fierce competition in the Latin American e-commerce market leading to short-term profit declines, its investments in financial services are set to lay the groundwork for future growth, particularly in underbanked regions, potentially yielding substantial returns in the long run.
- Visa's Legal Challenges: Visa is currently under pressure from antitrust lawsuits and proposed legislation in the U.S., which may impact its outlook; however, the company's solid financial performance and network effects keep it competitively strong in the payments industry, making it an attractive long-term investment.
- Market Reaction and Investment Opportunities: Despite the stock price declines of HCA Healthcare, MercadoLibre, and Visa due to company-specific issues, their leadership positions and future growth potential in their respective fields make them worthy of attention during market fluctuations, presenting buying opportunities for investors.
See More
Healthcare Stocks Surge Following CMS Payment Rate Proposal
- Healthcare Stocks Surge: Following the CMS proposal to increase payment rates by 2.4% for hospitals and ambulatory surgical centers, shares of Universal Health Services rose 7% and HCA Healthcare increased by 5%, reflecting market optimism towards the healthcare sector.
- Rivian's Delivery Outlook Raised: Rivian Automotive raised its 2026 delivery outlook from 62,000-67,000 to 65,000-70,000, resulting in an 8% stock price increase, indicating strong market confidence in its future growth potential.
- Blue Owl Capital Redemption Pressure Eases: Blue Owl Capital's stock jumped over 4% as a shareholder letter revealed that redemption requests for its private credit funds decreased to $4.7 billion in Q2 from $5.4 billion in Q1, suggesting improved market confidence in its liquidity.
- National Beverage's Special Cash Dividend: National Beverage Corp. announced a special cash dividend of $3.25 per share, leading to a 13% stock price increase, which not only enhances investor returns but may also attract more attention from potential investors.
See More
HCA Healthcare Launches Gene Editing Therapy Research for Children
- Significant Research Findings: HCA Healthcare's study published in The New England Journal of Medicine demonstrates promising results for gene editing therapy in children aged 5-11 with severe sickle cell disease and transfusion-dependent beta thalassemia, with all eight beta thalassemia patients achieving transfusion independence for at least 12 months, highlighting the potential for earlier intervention.
- Clinical Trial Context: The study is based on two phase 3 trials enrolling 26 children, including 15 with beta thalassemia and 11 with sickle cell disease, emphasizing the importance of gene editing therapy in alleviating the disease burden in children.
- Innovative Treatment Mechanism: The therapy works by editing patients' own blood-forming stem cells to increase fetal hemoglobin production, which can help prevent or reduce disease complications, showcasing the application prospects of gene editing technology in blood disorder treatments.
- Expanding Treatment Opportunities: HCA Healthcare is expanding access to FDA-approved gene editing therapies through its Sarah Cannon Transplant and Cellular Therapy Network, with TriStar Centennial Children's Hospital in Nashville and Methodist Children's Hospital in San Antonio currently offering treatments, and Medical City Children's Hospital in Dallas preparing to expand services.
See More
HCA Healthcare Rated as Top Non-Tech Stock by Analysts
- Price Target Cut: TD Cowen has lowered HCA Healthcare's price target from $500 to $431 while maintaining a Buy rating, reflecting a cautious outlook on the company's future growth, particularly after reducing growth assumptions for 2026 and 2027.
- Stagnant Revenue Growth: The May hospital survey indicated flat year-over-year revenue for HCA Healthcare, with weaker surgical volumes partially offset by growth in medical volumes, which could impact the company's overall financial performance.
- Acquisition of Educational Institution: On May 27, HCA Healthcare announced the acquisition of The College of Health Care Professions (CHCP), which educates over 8,000 students annually, highlighting the company's commitment to academic quality and student success while enhancing its talent pipeline in the healthcare sector.
- Long-term Partnership: HCA Healthcare has partnered with CHCP for decades, primarily through clinical sites, program advisory boards, and career placement, and this deep-rooted collaboration is expected to further strengthen the company's influence in healthcare education.
See More
Opportunities in Investing in Quality Stocks on the Dip
- HCA Healthcare Outlook: Despite HCA Healthcare's stock price decline due to economic challenges, its extensive facility network and industry leadership position make it an attractive long-term investment, especially as the aging population drives demand for services.
- MercadoLibre's Strategic Investments: Facing competitive pressures in the Latin American e-commerce market, MercadoLibre's short-term profit decline is offset by investments in financial services and advertising, which are expected to lay the groundwork for future growth and showcase its market potential.
- Visa's Legal Challenges: While Visa is under pressure from antitrust lawsuits and legislative proposals, its strong financial performance and network effects maintain its competitiveness in the digital payments space, indicating continued long-term return potential.
- Market Performance Comparison: Although HCA Healthcare, MercadoLibre, and Visa have recently underperformed, their robust fundamentals suggest that investors should consider increasing their positions during this downturn to potentially reap substantial rewards in the future.
See More
Investment Opportunities in HCA, MercadoLibre, and Visa Amidst Market Challenges
- HCA Healthcare's Market Position: HCA Healthcare boasts a vast network of facilities across the U.S., and despite facing economic challenges, it continues to grow its market share, showcasing its competitive advantage in a high-barrier industry that attracts long-term investors.
- MercadoLibre's Strategic Investments: Facing intense e-commerce competition, MercadoLibre is heavily investing in financial services to establish a leading position in the long run, even though short-term profits and margins are affected, its future potential remains promising.
- Visa's Legal Challenges: Visa is under pressure from antitrust lawsuits and proposed legislation, yet its strong financial performance and network effects position it well for long-term growth in the digital payment space, making it a worthwhile consideration for investors.
- Opportunities for Market Rebound: Despite declines in stock prices due to company-specific issues, HCA, MercadoLibre, and Visa's leadership positions and future growth potential make them attractive investments as the market recovers.
See More
Healthcare, E-commerce, and Payment Giants Face Challenges
- HCA Healthcare's Market Position: HCA Healthcare boasts a vast network of facilities across the U.S., and despite facing economic challenges and high inflation, it continues to grow its market share, demonstrating strong competitiveness in the healthcare sector, making it a buy on dips for long-term investors.
- MercadoLibre's Investment Strategy: Although MercadoLibre faces fierce competition in the Latin American e-commerce market leading to short-term profit declines, its investments in financial services are set to lay the groundwork for future growth, particularly in underbanked regions, potentially yielding substantial returns in the long run.
- Visa's Legal Challenges: Visa is currently under pressure from antitrust lawsuits and proposed legislation in the U.S., which may impact its outlook; however, the company's solid financial performance and network effects keep it competitively strong in the payments industry, making it an attractive long-term investment.
- Market Reaction and Investment Opportunities: Despite the stock price declines of HCA Healthcare, MercadoLibre, and Visa due to company-specific issues, their leadership positions and future growth potential in their respective fields make them worthy of attention during market fluctuations, presenting buying opportunities for investors.
See More
